191,578 Shares in Ultragenyx Pharmaceutical Inc. $RARE Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent filing with the SEC. The firm acquired 191,578 shares of the biopharmaceutical company’s stock, valued at approximately $6,397,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares during the last quarter. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $454,000. American Century Companies Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $366,000. M&T Bank Corp increased its stake in shares of Ultragenyx Pharmaceutical by 19.7% during the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 1,192 shares during the period. Finally, Amundi increased its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% during the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after acquiring an additional 93,189 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 8,552 shares of company stock worth $207,455. 5.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on RARE shares. Royal Bank Of Canada increased their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Wedbush dropped their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. JPMorgan Chase & Co. increased their target price on Ultragenyx Pharmaceutical from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Wells Fargo & Company raised their price target on Ultragenyx Pharmaceutical from $45.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $59.22.

Ultragenyx Pharmaceutical Stock Down 0.1%

NASDAQ:RARE opened at $26.44 on Thursday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $39.89. The stock has a market cap of $2.61 billion, a PE ratio of -4.53 and a beta of 0.35. The firm’s fifty day simple moving average is $28.61 and its 200-day simple moving average is $25.01.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same quarter last year, the firm posted ($1.17) EPS. The business’s revenue was up 28.5% compared to the same quarter last year. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.99 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.